Abingworth Overview
Abingworth LLP is a transatlantic life sciences investment firm founded in 1973. With offices in London, Menlo Park (California), and Boston, Abingworth provides capital and expertise to management teams building world-class companies. Since its inception, Abingworth has invested in over 185 life science companies, leading to more than 75 IPOs and over 50 mergers and acquisitions. The firm's investments focus on three categories: seed and early-stage, development stage, and clinical co-development. In August 2022, Abingworth became part of The Carlyle Group.
Is Abingworth the right investor for your startup? Browse their investment focus, stage preferences, and geographic scope to see how well they align with your fundraising goals. Your full match score with Abingworth, along with a list of other relevant VCs, is available on Hopohopo.io.
Abingworth
Investment focus
Product type
- Drugs / Pharma
Industries / verticals
- BioTech & Life Sciences
- MedTech & Devices
- PharmaTech
Investment role
Lead and follow
Stages
Seed, Series A, Series B or later
First ticket size
US$15,000,000 - US$30,000,000
Contact information
Principal
Lucille Conroy
Principal
Diya Malhotra
Principal
Graham Mills
Venture Partner
Natalie Mount
Managing Partner, Chief Investment Officer
Bali Muralidhar
How to approach funds like Abingworth
When engaging Abingworth, founders should highlight robust clinical or development-stage milestones and a clear path to value inflection, as the firm is known for hands-on involvement and deep sector expertise. Emphasize your team’s track record in navigating regulatory and clinical hurdles, and be prepared to discuss how your science or platform can scale to address significant unmet needs. Abingworth values collaborative partnerships and often co-creates development plans, so openness to strategic input and alignment on long-term vision will resonate strongly.
Find the best-fitting investors for your startup
Stop wasting weeks searching for the right investors. Upload your deck and get matched with investors who actually fit your startup — so you can focus on building, not chasing.
